BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
01/06/2022
Initial Lawsuit
04/01/2022
Lawsuit Progression
07/07/2022
This investigation focuses on information provided in a short report by The Bear Cave regarding company patents, competition and “economic substance.”
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We update this post regularly.
01/06/2022
The Bear Cave publishes a short report alleging, among other issues, “that Embark appears to lack true economic substance” and that its “current evaluation appears to be based on puffery rather than actual substance” because “[t]he company holds no patents, has only a dozen or so test trucks, and may be more bark than bite.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$6.81 | $8.18 | $-1.37 | -16.75% |
An Embark Technology, Inc. (EMBK) investor filed a federal securities class action lawsuit on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired Embark securities between January 12, 2021, and January 5, 2022, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Northern Genesis Acquisition Corp. II had performed inadequate due diligence into former Embark Trucks Inc.;
(ii) Embark Trucks Inc., and Northern Genesis Acquisition following the business combination held no patents and an insignificant amount of test trucks;
(iii) accordingly, the company had overstated its operational and technological capabilities;
(iv) as a result of all the foregoing, the company had overstated the business and financial prospects of the company post business combination; and
(v) as a result, the company’s public statements were materially false and
misleading at all relevant times.
07/07/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.